Premium
Does growth hormone treatment of patients with Turner's syndrome cause an abnormal body shape?
Author(s) -
Gerver WJM,
Drayer NM,
Es A
Publication year - 1992
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1992.tb12335.x
Subject(s) - medicine , turner syndrome , turner's syndrome , hormone , growth hormone , sitting , body surface area , body height , body weight , endocrinology , pathology
The effect of human growth hormone on the body shape of 51 patients with Turner's syndrome (aged 6–19 years) was evaluated. Biosynthetic growth hormone was given in a dose of 24 IU/m 2 body surface/week for two years. Karyotype analysis on peripheral blood was performed. Patients older than 12 years also received 0.1 μg ethinyl oestradiol/kg body weight/day orally. Body shape was characterized by studying pairs of measurements expressed as SD scores (z scores). As reference data, our own locally obtained data from normal children were used. After two years of growth hormone therapy, height, sitting height, biacromial and biiliac diameter increased from –3.7, –2.9, –1.7 and –1.2 to –1.3, –2.5, –0.6 and +0.5 z scores, respectively. The shape of the patients, expressed as height/biiliac diameter and also as sitting height/biiliac diameter became more abnormal. As no difference could be noted between the prepubertal and pubertal groups or between the XO and mosaic groups, it is suggested that growth hormone treatment causes a relatively wide pelvis in patients with Turner's syndrome.